At a glance
| Sequence shorthand | Pal-GHK |
|---|---|
| Common blend | Matrixyl 3000 |
| Different compound | GHK-Cu / copper tripeptide-1 |
| Common co-ingredient | Palmitoyl tetrapeptide-7 |
| Evidence limitation | Most human data concern complete formulations |
Overview
This ingredient links palmitic acid to glycine-histidine-lysine. The modification changes the molecule from unbound GHK and from the copper complex GHK-Cu. Those related names are easy to confuse, but evidence cannot move between them without justification. Palmitoyl tripeptide-1 commonly appears alongside palmitoyl tetrapeptide-7 in a commercial blend and with multiple other actives in finished products. Its proposed role is signaling rather than supplying bulk collagen to fill the skin. The relevant question is whether a defined topical product improves a measured outcome beyond its vehicle, and whether any improvement can specifically be assigned to this peptide.
How it works
The cosmetic rationale is based on a matrix-fragment signaling concept associated with the GHK sequence, with palmitoylation used to modify formulation behavior. That does not establish identical activity to GHK-Cu, since copper coordination and lipid attachment are different chemical changes. Penetration, stability, and the surrounding formulation determine exposure. A theoretical collagen-related signal therefore needs direct confirmation in the final product and population.
A relevant multi-component eye-cream study
A 2024 publication evaluated an active complex containing palmitoyl tripeptide-1, palmitoyl tetrapeptide-7, fermentation filtrate, and N-acetylneuraminic acid. Laboratory and twelve-week human measurements supported further investigation of the formula. The design cannot assign the outcome solely to palmitoyl tripeptide-1 or establish the same performance in an unrelated serum.
Supporting sources [1]
Why the copper distinction matters
The CIR document describes palmitoyl tripeptide-1 as lipid-modified GHK, while copper tripeptide-1 is a metal complex. A study of one should not automatically populate the other’s benefit claims. The same rule applies to Matrixyl 3000: its two peptides remain distinct molecules even when sold together.
Read safety in the correct context
Cosmetic status is not FDA drug approval. The ingredient-family assessment concerns described topical practices, not injected use. Whole-product irritation, stability, and formulation compatibility remain relevant, and absence of a serious event in a small cosmetic study cannot establish unlimited or long-term safety.
Reading this profile
Jurisdiction: United States; status and indications may differ elsewhere. Molecular class: Palmitoylated glycine-histidine-lysine tripeptide.
This profile was written with AI-assisted research and checked against the linked sources. It has not been represented as a clinician’s review. Evidence summaries describe the cited studies and products; they do not establish that a separately purchased preparation is equivalent.
Sources & references
Follow the original material. Product labels define specific formulations and uses; trial registration describes a study and does not by itself establish benefit.
- Multi-component eye cream including palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7 ↗Clinical trial source · Checked 2026-10-27
- CIR final safety assessment: tripeptide-1, hexapeptide-12, derivatives, and palmitoyl tetrapeptide-7 ↗Ingredient assessment · Checked 2026-10-27
- Croda: Matrixyl 3000 ingredient composition and supplier claims ↗Manufacturer / sponsor · Checked 2026-10-27
- FDA: authority over cosmetics and the distinction from drug approval ↗Regulatory source · Checked 2026-10-27